Catalyst Wire Dossier Catalyst Wire Dossier

EGFR-TKIs

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EGFR-TKIs, covering 2018-10-25 to 2018-10-25. Get the full timeline:

Most recent: Clinical Trial Update: EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC [Phase 2]

See pricing